FLT3 and leukemia: Beyond the HOXA axis, this oncogenic program also drives the expression of other critical survival genes, such as the anti-apoptotic factor BCL-2 and the stem cell marker FLT3 (FMS-like tyrosine kinase 3), both of which contribute to the leukemia’s survival and chemoresistance [19].